Ultra-short-acting selective beta-1 blocker
Pregnancy: Use with caution. Fetal bradycardia possible.
Esmolol
Brand names: Brevibloc
Adult dose
Dose: 500 mcg/kg IV loading over 1 min; maintenance 50–200 mcg/kg/min
Route: IV infusion
Frequency: Continuous infusion
Max: 200 mcg/kg/min (maintenance)
SVT/AF with rapid ventricular response: 500 mcg/kg over 1 min, then 50–100 mcg/kg/min maintenance, titrate to HR. Acute aortic dissection: combine with IV vasodilator (GTN/nitroprusside). Perioperative tachycardia: IV bolus 500 mcg/kg, then infusion.
Paediatric dose
Dose: 500 micrograms/kg
Route: IV
Frequency: Loading bolus over 1 min, then 50–200 micrograms/kg/min infusion
Max: 500 micrograms/kg loading; 200 micrograms/kg/min maintenance
Concentration: 10000 micrograms/ml
BNFc paediatric cardiology specialist use: loading 500 micrograms/kg IV over 1 min, then maintenance infusion 50–200 micrograms/kg/min titrated to HR. SVT/AF with rapid ventricular response; perioperative tachycardia; thyroid storm. Half-life 2–9 min — rapid offset on stopping.
Dose adjustments
Renal
No dose adjustment required.
Hepatic
No dose adjustment required (hydrolysed by red blood cell esterases).
Paediatric weight-based calculator
BNFc paediatric cardiology specialist use: loading 500 micrograms/kg IV over 1 min, then maintenance infusion 50–200 micrograms/kg/min titrated to HR. SVT/AF with rapid ventricular response; perioperative tachycardia; thyroid storm. Half-life 2–9 min — rapid offset on stopping.
Clinical pearls
- Half-life 9 minutes — effects resolve within 20–30 minutes of stopping (ideal for titration)
- Ideal for perioperative tachycardia/hypertension — rapidly on/off
- Rate control in AF/SVT: when full effect needed quickly and reversibility important
- Aortic dissection: first-line IV beta-blocker (combined with vasodilator)
- 10 mg/mL solution requires dilution for peripheral use (use 250 mg/mL bags for central infusion)
Contraindications
- Asthma (severe)
- Severe bradycardia or AV block
- Cardiogenic shock
- Cocaine toxicity
Side effects
- Hypotension
- Bradycardia
- Bronchospasm
- Phlebitis at infusion site (concentrated solution — prefer central or large vein)
Interactions
- Digoxin — additive bradycardia
- Verapamil/diltiazem — AV block risk
- MAOIs — hypertensive crisis
Monitoring
- Continuous ECG
- BP every 5 min
- HR
- SpO2
Reference: BNFc; BNF; ESC AF/ACS Guidelines; ACEP Arrhythmia Management. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology
Pathways
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
- Syncope Assessment · ESC 2018 Syncope Guidelines; NICE NG109
- Acute Chest Pain · NICE CG95; ESC 2023 ACS Guidelines